M

Microba Life Sciences Ltd
ASX:MAP

Watchlist Manager
Microba Life Sciences Ltd
ASX:MAP
Watchlist
Price: 0.195 AUD 5.41% Market Closed
Market Cap: 87.3m AUD
Have any thoughts about
Microba Life Sciences Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one MAP stock under the Base Case scenario is 0.293 AUD. Compared to the current market price of 0.195 AUD, Microba Life Sciences Ltd is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAP Relative Value
Base Case
0.293 AUD
Undervaluation 33%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

7.2
P/S
P/S
Price to Sales
7.2
vs History
84
vs Industry
12
Median 3Y
12.7
Median 5Y
12.7
Industry
2.3
Forward
4.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-5.6
Industry
23.2
Forward
-6.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-5.9
Industry
14.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.8
Industry
20.1
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
66
vs Industry
50
Median 3Y
2
Median 5Y
2
Industry
2.2
More Details
5.5
EV/S
EV/S
Enterprise Value to Sales
5.5
vs History
84
vs Industry
16
Median 3Y
8.3
Median 5Y
8.3
Industry
2.4
Forward
3.7
More Details
11.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.3
vs History
84
vs Industry
12
Median 3Y
17.5
Median 5Y
17.5
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.8
Industry
12.8
Forward
-4.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.8
Industry
17.2
Forward
-3.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-4
Median 5Y
-4
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.2
Industry
18.2
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
87
vs Industry
44
Median 3Y
3
Median 5Y
3
Industry
1.9
More Details

Multiples Across Competitors

MAP Competitors Multiples
Microba Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Microba Life Sciences Ltd
ASX:MAP
87.3m AUD 7.2 -4.4 -3.2 -3.2
US
Cigna Group
XMUN:CGN
75.6B EUR 0.3 25.9 8.1 10.4
US
Cigna Corp
NYSE:CI
77.9B USD 0.3 25.6 8 10.3
US
CVS Health Corp
NYSE:CVS
56B USD 0.2 11.2 9.6 9.6
DE
Fresenius Medical Care AG
XMUN:FME
26B EUR 1.3 49 11.2 25.9
DE
Fresenius SE & Co KGaA
XETRA:FRE
18.8B EUR 0.9 -49.2 9.3 19
US
Laboratory Corporation of America Holdings
NYSE:LH
19.3B USD 1.5 44.3 13.2 20.4
US
R1 RCM Inc
NASDAQ:RCM
16.9B USD 6.9 -275.9 36.7 94.9
US
Quest Diagnostics Inc
NYSE:DGX
17.1B USD 1.8 20.4 12.3 16.6
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13B EUR 0.7 24.5 7.1 16.4
US
DaVita Inc
NYSE:DVA
12.7B USD 1 15.4 8 11.1
P/E Multiple
Earnings Growth PEG
AU
M
Microba Life Sciences Ltd
ASX:MAP
Average P/E: 27
Negative Multiple: -4.4 		N/A N/A
US
C
Cigna Group
XMUN:CGN
25.9
25%
1
US
Cigna Corp
NYSE:CI
25.6
25%
1
US
CVS Health Corp
NYSE:CVS
11.2
3%
3.7
DE
Fresenius Medical Care AG
XMUN:FME
49
31%
1.6
DE
Fresenius SE & Co KGaA
XETRA:FRE
Negative Multiple: -49.2 N/A N/A
US
Laboratory Corporation of America Holdings
NYSE:LH
44.3
54%
0.8
US
R1 RCM Inc
NASDAQ:RCM
Negative Multiple: -275.9
253%
N/A
US
Quest Diagnostics Inc
NYSE:DGX
20.4
12%
1.7
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
24.5
31%
0.8
US
DaVita Inc
NYSE:DVA
15.4
17%
0.9

See Also

Summary
MAP intrinsic value, competitors valuation, and company profile.
DCF Valuation
MAP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MAP stock valuation using valuation multiples.
Wall Street Estimates
MAP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MAP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.